Christine Luk Chiang Johnson, MD
Neonatal-Perinatal Medicine · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Johnson’s office at (650) 497-8000 to ask if they take your plan before you enroll.
California Medical Board record
Licence A111726 · Current
Licensed to practise in California · since 2010 · expires 2027-12-31 · University of Southern California Keck School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Pediatrics - Neonatal-Perinatal Medicine
- American Board of Pediatrics - Pediatrics
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their 18 Part D prescriptions in 2013. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| United Therapeutics Corporation · Intravenous Remodulin (Treprostinil) As Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized Placebo-Controlled Safety and Efficacy Study · 2021 | Their institution | $5,018 |
| United Therapeutics Corporation · Intravenous Remodulin (Treprostinil) As Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized Placebo-Controlled Safety and Efficacy Study · 2022 | Their institution | $1,280 |
| United Therapeutics Corporation · Intravenous Remodulin Treprostinil As Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn A Randomized Placebo-Controlled Safety and Efficacy Study · 2019 | Their institution | $300 |
Professional record
- NPI
- 1861685349
- Licence
- CA A111726California A111726: Current · expires 2027-12-31
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080N0001X (2080N0001X); Pediatrics (208000000X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2007-08-20
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.